ADC Therapeutics SA To Discuss the highlighting of ADC Platform and Solid Tumor Pipeline Call Transcript
Good morning, good afternoon. I'm Eugenia Litz, Investor Relations at ADC Therapeutics. It is my pleasure to welcome you to our webcast today, highlighting our ADC platform and solid tumor pipeline.
I would like to remind you that this presentation may contain forward-looking statements, which are subject to certain risks and uncertainties. Please refer to our SEC filings for more information.
On our call today is Chris Martin, our CEO; Patrick van Berkel, our Head of R&D; and Joe Camardo, our Chief Medical Officer. And with that, it is my pleasure to turn the call over to Chris.
Thank you, Eugenia, and welcome to the ADCT pipeline -- solid tumor pipeline call. It was almost exactly 20 years ago that I sat down and met John Hartley in University College London to look at some pyrrolobenzodiazepines data in a couple of solid tumor models, in cisplatin resistant ovarian and glioma. These PBDs have been designed specifically to be active in hard to treat
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
